Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NETSTREIT Corp. (NTST)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Passage Bio, Inc. (PASG)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system, or CNS, disorders with limited or no approved treatment options. Their vision is to become the premier genetic medicines company by developing and ultimately commercializing therapies that dramatically and positively transform the lives of patients suffering from these life-threatening disorders. To achieve their vision, they have assembled a world-class team whose members have decades of collective experience in genetic medicines and rare disease drug development and commercialization. The field of genetic medicine is rapidly expanding and they believe they have a differentiated approach to developing treatments for rare, monogenic CNS disorders that enables them to select and advance product candidates with a higher probability of technical and regulatory success. They have entered into a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, headed by Dr. James Wilson, a leader in the genetic medicines field.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Bruce A. Goldsmith Richard S. Morris
Employees Founded
20 2017

Contacts

Address: Two Commerce Square, 2001 Market Street, 28th Floor, Philadelphia, PA, 19103, US

Telephone: (267) 866-0311

Web page: http://www.passagebio.com

IPO information

Expected Date 2/28/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $714.0
Revenues (MM) $0
Net Income (Loss) (MM) $-45.6

Voting

What do you think will happen with the PASG share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 7.4
Shares Revised (MM) 12
Expected offer amount (MM) $216
Realized offer amount(MM) $216
Underwriters
JP Morgan/ Goldman Sachs/ Cowen
CO-Managers
Chardan

Sector: Healthcare

Tweets about $PASG

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats